Murray A M, Waddington J L
Department of Clinical Pharmacology, Royal College of Surgeons, Dublin, Ireland.
Eur J Pharmacol. 1990 Sep 4;186(1):79-86. doi: 10.1016/0014-2999(90)94062-3.
Studies were undertaken to clarify further the mechanism(s) of action of the atypical neuroleptic clozapine, using a behavioural model with the ability to distinguish between relative antagonism of D1 vs. D2 dopamine receptor-mediated function. Pretreatment with low doses of clozapine (2.5-25.0 mg/kg) readily antagonised intense grooming induced by the selective D1 agonist SK&F 77434 (0.75 mg/kg), and in a less consistent manner antagonised hyperactivities induced by the selective D2 agonist LY 163502 (0.05 mg/kg). In animals whose typical responses to SK&F 77434 were antagonised by clozapine, no atypical behaviours such as vacuous chewing emerged. However, in animals whose typical responses to LY 163502 were antagonised by clozapine, a syndrome of atypical limb/body jerking was released. Despite clozapine showing comparable affinities for D1 and D2 receptors in vitro, this behavioural profile shows similarities to that seen when these agonists are given after pretreatment with a selective D1 antagonist, rather than with a selective D2 antagonist or with non-selective neuroleptics. These results suggest that clozapine has some preferential though not selective action in vivo to antagonise D1 dopamine receptor-mediated function.
开展了多项研究,以进一步阐明非典型抗精神病药物氯氮平的作用机制,采用一种行为模型,该模型能够区分D1和D2多巴胺受体介导功能的相对拮抗作用。用低剂量氯氮平(2.5 - 25.0毫克/千克)预处理可轻易拮抗由选择性D1激动剂SK&F 77434(0.75毫克/千克)诱导的强烈梳理行为,并且以不太一致的方式拮抗由选择性D2激动剂LY 163502(0.05毫克/千克)诱导的多动。在其对SK&F 77434的典型反应被氯氮平拮抗的动物中,未出现诸如空嚼等非典型行为。然而,在其对LY 163502的典型反应被氯氮平拮抗的动物中,出现了一种非典型肢体/身体抽搐综合征。尽管氯氮平在体外对D1和D2受体显示出相当的亲和力,但这种行为特征与在用选择性D1拮抗剂而非选择性D2拮抗剂或非选择性抗精神病药物预处理后给予这些激动剂时所观察到的相似。这些结果表明,氯氮平在体内具有一些优先但非选择性的作用,以拮抗D1多巴胺受体介导的功能。